Sidoti Expects Reduced Earnings for USANA Health Sciences

USANA Health Sciences, Inc. (NYSE:USNA) – Equities research analysts at Sidoti lowered their Q2 2026 earnings estimates for shares of USANA Health Sciences in a report released on Tuesday, April 21st. Sidoti analyst A. Lebiedzinski now anticipates that the company will post earnings per share of $0.43 for the quarter, down from their prior estimate of $0.45. The consensus estimate for USANA Health Sciences’ current full-year earnings is $1.95 per share. Sidoti also issued estimates for USANA Health Sciences’ Q4 2026 earnings at $0.65 EPS and FY2026 earnings at $1.95 EPS.

USANA Health Sciences (NYSE:USNA) last released its quarterly earnings data on Tuesday, February 17th. The company reported $0.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.41 by $0.19. USANA Health Sciences had a net margin of 1.16% and a return on equity of 6.75%. The business had revenue of $226.20 million during the quarter, compared to analysts’ expectations of $225.96 million.

A number of other brokerages have also weighed in on USNA. Weiss Ratings restated a “sell (d)” rating on shares of USANA Health Sciences in a research report on Friday, March 27th. Wall Street Zen raised USANA Health Sciences from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Finally, Zacks Research upgraded USANA Health Sciences from a “hold” rating to a “strong-buy” rating in a report on Monday, April 13th. One analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy”.

USANA Health Sciences Stock Performance

NYSE USNA opened at $19.23 on Thursday. The firm’s fifty day moving average price is $18.69 and its two-hundred day moving average price is $19.95. The stock has a market cap of $354.91 million, a PE ratio of 34.96, a PEG ratio of 0.83 and a beta of 0.71. USANA Health Sciences has a fifty-two week low of $16.60 and a fifty-two week high of $38.32.

Institutional Trading of USANA Health Sciences

Several institutional investors have recently added to or reduced their stakes in USNA. Pzena Investment Management LLC raised its holdings in USANA Health Sciences by 1.2% during the 3rd quarter. Pzena Investment Management LLC now owns 1,212,588 shares of the company’s stock worth $33,407,000 after purchasing an additional 14,328 shares during the last quarter. Renaissance Technologies LLC boosted its stake in shares of USANA Health Sciences by 1.9% in the 4th quarter. Renaissance Technologies LLC now owns 1,147,323 shares of the company’s stock valued at $22,522,000 after purchasing an additional 21,793 shares during the last quarter. Vanguard Group Inc. increased its position in shares of USANA Health Sciences by 5.7% during the third quarter. Vanguard Group Inc. now owns 1,069,032 shares of the company’s stock worth $29,452,000 after buying an additional 57,249 shares during the period. Dimensional Fund Advisors LP raised its stake in USANA Health Sciences by 1.9% during the third quarter. Dimensional Fund Advisors LP now owns 915,049 shares of the company’s stock worth $25,210,000 after buying an additional 17,318 shares during the last quarter. Finally, Nantahala Capital Management LLC bought a new position in USANA Health Sciences during the fourth quarter worth $11,485,000. 54.25% of the stock is currently owned by institutional investors.

Insider Activity at USANA Health Sciences

In other USANA Health Sciences news, insider Joshua Foukas sold 4,461 shares of the company’s stock in a transaction dated Friday, February 20th. The stock was sold at an average price of $21.34, for a total value of $95,197.74. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 0.82% of the company’s stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.